Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
AlloVir, Inc. (ALVR) closed the last trading session at $7.65, gaining 9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
Shares of AlloVir, Inc. (ALVR) have gained 2.7% over the past four weeks to close the last trading session at $6.03, but there could still be a solid upside left in the stock if short-term price ...
AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both ...
Gilead has purchased $10.9 million in shares of AlloVir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownership of the company. AlloVir's lead product, ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results